Capital 10X – Pot Stocks Weekly Performance Wrap (December 6th, 2019)

Below is a comparison of the biggest winners and losers in PotStocks this week, grouped by market cap and country. See whether your picks are outperforming or if you need to rebalance your portfolio.

The High Level

Last week was another disappointing week for PotStocks, with U.S. and Canadian small-cap groups both down over 10%, while no group managed to have a positive week as a whole.

Starting with large caps, TGOD led the way with an 8% gain on no discernible news. TGOD now sits at $0.80/share, up $0.18 from their all-time low. On the opposite end, Tilray fell 8%, again on no news and up only $0.20 from their 52-week low.

The U.S. large caps were led once again by Trulieve, with a modest 4% gain. The company continues to benefit from solid operations and a burgeoning Florida market. With the largest production capacity in the space, they are well positioned to continue their growth.

Charlotte’s Web and GTII fell over 12% on the week. While CWEB was hurt by the recent announcement from the FDA that hurt the CBD industry, it’s unclear why GTII is suffering.

Mid-caps last week saw much more movement. Emerald Health led the way (downwards) with a 25% drop. The stock has been battered from the back and forth news regarding loss of ownership of the Pure SunFarms JV with Village Farms. Tensions boiled over this past week with shareholders — clearly, they have had enough.

Zenabis was also punished this week with a 12% drop due in large part to news surrounding the failure to obtain GMP certification for their facility. Even an update on operations by management didn’t satisfy investors.

The biggest gain for the week came from CannTrust (5%) after they released on update on the status of their restated financials and their “remediation efforts”.

In the U.S., there were no gains, with losses led by SLANG Worldwide (17%) after they announced the closing of a small financing, now priced at a premium to the current stock levels.

In the small-cap space, GTEC led the way with a 10% gain on decent volume. This jump comes after the retail debut of their product. MJardin led the way in the opposite direction with a massive 45% drop, likely due to analyst price target downgrades after disappointing earnings.

In the U.S., Liberty Health led the way with an 18% gain. We highlight some of the reasons in a deep-dive on the company. PLUS Products dropped 40% after earnings disappointed investors.

Pot Stocks Group Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Large-Cap Weekly Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Large-Cap YTD Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Mid-Cap Weekly Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Mid-Cap YTD Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Small-Cap Weekly Performance

Source: Yahoo Finance.

Canadian Pot Stocks – Small-Cap YTD Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Large-Cap Weekly Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Large-Cap YTD Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Mid-Cap Weekly Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Mid-Cap YTD Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Small-Cap Weekly Performance

Source: Yahoo Finance.

U.S. Pot Stocks – Small-Cap YTD Performance

Source: Yahoo Finance.
0 0 vote
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Evan Veryard
Evan Veryard has a Bachelor's of Chemical Engineering from McGill University and a MaSc. of Chemical Engineering from RMC. He has over 6 years of research experience focusing on industrial materials. Address: 682 Indian Road, Toronto, Ontario, M6P 2C9. Phone: 416-721-8257.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments